
LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Publications (431) LUIS GONZAGA PAZ-ARES RODRÍGUEZ publications
2025
-
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)
Journal of Thoracic Oncology
-
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Results From the Phase II TROPION-Lung05 Study
Journal of Clinical Oncology
-
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis
Journal of Thoracic Oncology, Vol. 20, Núm. 1, pp. 94-108
-
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer
Expert Review of Anticancer Therapy, Vol. 25, Núm. 1, pp. 27-40
2024
-
A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma
Redox Biology, Vol. 75
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816
-
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
Journal of Thoracic Oncology, Vol. 19, Núm. 2, pp. 285-296
-
CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
OncoImmunology, Vol. 13, Núm. 1
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 192-204
-
Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191
-
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial
Lung Cancer, Vol. 189
-
Correction to: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments (Drugs, (2024), 84, 5, (527-548), 10.1007/s40265-024-02030-7)
Drugs
-
Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
The Lancet Regional Health - Europe, Vol. 38
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
-
Durvalumab _ Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden
Clinical Cancer Research, Vol. 30, Núm. 4, pp. 824-835
-
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326
-
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
BMC Cancer, Vol. 23, Núm. Suppl 1
-
Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 985-990
-
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)
Lung Cancer, Vol. 187